Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients.
Burkitt lymphoma
immunochemotherapy
prognosis
real-world patients
survival
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
12
09
2019
accepted:
28
10
2019
pubmed:
6
2
2020
medline:
13
1
2021
entrez:
5
2
2020
Statut:
ppublish
Résumé
Non-endemic Burkitt lymphoma (BL) is a rare germinal centre B-cell-derived malignancy with the genetic hallmark of MYC gene translocation and with rapid tumour growth as a distinct clinical feature. To investigate treatment outcomes, loss of lifetime and relapse risk in adult BL patients treated with intensive immunochemotherapy, retrospective clinic-based and population-based lymphoma registries from six countries were used to identify 264 real-world patients. The median age was 47 years and the majority had advanced-stage disease and elevated LDH. Treatment protocols were R-CODOX-M/IVAC (47%), R-hyper-CVAD (16%), DA-EPOCH-R (11%), R-BFM/GMALL (25%) and other (2%) leading to an overall response rate of 89%. The two-year overall survival and event-free survival were 84% and 80% respectively. For patients in complete remission/unconfirmed, the two-year relapse risk was 6% but diminished to 0·6% for patients reaching 12 months of post-remission event-free survival (pEFS12). The loss of lifetime for pEFS12 patients was 0·4 (95% CI: -0·7 to 2) months. In conclusion, real-world outcomes of adult BL are excellent following intensive immunochemotherapy. For pEFS12 patients, the relapse risk was low and life expectancy similar to that of a general population, which is important information for developing meaningful follow-up strategies with increased focus on survivorship and less focus on routine disease surveillance.
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
661-671Informations de copyright
© 2020 British Society for Haematology and John Wiley & Sons Ltd.
Références
Austin, P.C. & Stuart, E.A. (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Statistics in Medicine, 34, 3661-3679.
Barnes, J.A., Lacasce, A.S., Feng, Y., Toomey, C.E., Neuberg, D., Michaelson, J.S., Hochberg, E.P. & Abramson, J.S. (2011) Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Annals of Oncology, 22, 1859-1864.
Benjamini, Y. & Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological), 57, 289-300.
Blum, K.A., Lozanski, G. & Byrd, J.C. (2004) Adult Burkitt leukemia and lymphoma. Blood, 104, 3009-3020.
Castillo, J.J., Winer, E.S. & Olszewski, A.J. (2013) Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. Cancer, 119, 3672-3679.
Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-López, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. Journal of Clinical Oncology, 17, 1244.
Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
Cheson, B.D., Fisher, R.I., Barrington, S.F., Cavalli, F., Schwartz, L.H., Zucca, E. & Lister, T.A. (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. Journal of Clinical Oncology, 32, 3059-3068.
Corazzelli, G., Frigeri, F., Russo, F., Frairia, C., Arcamone, M., Esposito, G., De Chiara, A., Morelli, E., Capobianco, G., Becchimanzi, C., Volzone, F., Saggese, M., Marcacci, G., De Filippi, R., Vitolo, U. & Pinto, A. (2012) RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma. British Journal of Haematology, 156, 234-244.
Costa, L.J., Xavier, A.C., Wahlquist, A.E. & Hill, E.G. (2013) Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood, 121, 4861-4866.
Dave, S.S., Fu, K., Wright, G.W., Lam, L.T., Kluin, P., Boerma, E.-J., Greiner, T.C., Weisenburger, D.D., Rosenwald, A., Ott, G., Müller-Hermelink, H.-K., Gascoyne, R.D., Delabie, J., Rimsza, L.M., Braziel, R.M., Grogan, T.M., Campo, E., Jaffe, E.S., Dave, B.J., Sanger, W., Bast, M., Vose, J.M., Armitage, J.O., Connors, J.M., Smeland, E.B., Kvaloy, S., Holte, H., Fisher, R. I., Miller, T.P., Montserrat, E., Wilson, W.H., Bahl, M., Zhao, H., Yang, L., Powell, J., Simon, R., Chan, W.C. & Staudt, L.M. (2006) Molecular diagnosis of Burkitt's lymphoma. The New England Journal of Medicine, 354, 2431-2442.
Diviné, M., Casassus, P., Koscielny, S., Bosq, J., Sebban, C., Le Maignan, C., Stamattoulas, A., Dupriez, B., Raphaël, M., Pico, J.L. & Ribrag, V. (2005) Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Annals of Oncology, 16, 1928-1935.
Dunleavy, K., Pittaluga, S., Shovlin, M., Steinberg, S.M., Cole, D., Grant, C., Widemann, B., Staudt, L.M., Jaffe, E.S., Little, R.F. & Wilson, W.H. (2013) Low-intensity therapy in adults with Burkitt's lymphoma. New England Journal of Medicine, 369, 1915-1925.
Ederer, F., Axtell, L.M. & Cutler, S.J. (1961) The relative survival rate: a statistical methodology. National Cancer Institute Monograph, 6, 101-121.
Evens, A.M., Carson, K.R., Kolesar, J., Nabhan, C., Helenowski, I., Islam, N., Jovanovic, B., Barr, P.M., Caimi, P.F., Gregory, S.A. & Gordon, L.I. (2013) A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. Annals of Oncology, 24, 3076-3081.
Grambsch, P.M. & Therneau, T.M. (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika, 81, 515-526.
Hoelzer, D., Ludwig, W.D., Thiel, E., Gassmann, W., Löffler, H., Fonatsch, C., Rieder, H., Heil, G., Heinze, B., Arnold, R., Hossfeld, D., Büchner, T., Koch, P., Freund, M., Hiddemann, W., Maschmeyer, G., Heyll, A., Aul, C., Faak, T., Kuse, R., Ittel, T.H., Gramatzki, M., Diedrich, H., Kolbe, K. & Uberla, K. (1996) Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood, 87, 495-508.
Hoelzer, D., Walewski, J., Döhner, H., Viardot, A., Hiddemann, W., Spiekermann, K., Serve, H., Dührsen, U., Hüttmann, A., Thiel, E., Dengler, J., Kneba, M., Schaich, M., Schmidt-Wolf, I.G.H., Beck, J., Hertenstein, B., Reichle, A., Domanska-Czyz, K., Fietkau, R., Horst, H.A., Rieder, H., Schwartz, S., Burmeister, T. & Gökbuget, N. (2014) Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: Report of a large prospective multicenter trial. Blood, 124, 3870-3879.
Howard, S.C., Jones, D.P. & Pui, C.-H. (2011) The tumor lysis syndrome. The New England Journal of Medicine, 364, 1844-1854.
Intermesoli, T., Rambaldi, A., Rossi, G., Delaini, F., Romani, C., Pogliani, E.M., Pagani, C., Angelucci, E., Terruzzi, E., Levis, A., Cassibba, V., Mattei, D., Gianfaldoni, G., Scattolin, A.M., Di Bona, E., Oldani, E., Parolini, M., Gokbuget, N. & Bassan, R. (2013) High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica, 98, 1718-1725.
Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
Lacasce, A., Howard, O., Li, S., Fisher, D., Weng, A., Neuberg, D. & Shipp, M. (2004) Modified Magrath regimens for adults with burkitt and burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leukemia & Lymphoma, 45, 761-767.
Magrath, I.T., Janus, C., Edwards, B.K., Spiegel, R., Jaffe, E.S., Berard, C.W., Miliauskas, J., Morris, K. & Barnwell, R. (1984) An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood, 63, 1102-1111.
Magrath, I., Adde, M., Shad, A., Venzon, D., Seibel, N., Gootenberg, J., Neely, J., Arndt, C., Nieder, M., Jaffe, E., Wittes, R.A. & Horak, I.D. (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. Journal of Clinical Oncology, 14, 925-934.
Martinussen, T. & Scheike, T.H. (2006) Dynamic Regression Models for Survival Data New York. Springer, New York, NY.
Maurer, M.J., Ghesquières, H., Jais, J.-P., Witzig, T.E., Haioun, C., Thompson, C.A., Delarue, R., Micallef, I.N., Peyrade, F., Macon, W.R., Jo Molina, T., Ketterer, N., Syrbu, S.I., Fitoussi, O., Kurtin, P.J., Allmer, C., Nicolas-Virelizier, E., Slager, S.L., Habermann, T.M., Link, B.K., Salles, G., Tilly, H. & Cerhan, J.R. (2014) Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. Journal of Clinical Oncology, 32, 1066-1073.
Maurer, M.J., Ghesquières, H., Link, B.K., Jais, J.-P., Habermann, T.M., Thompson, C.A., Haioun, C., Allmer, C., Johnston, P.B., Delarue, R., Micallef, I.N., Peyrade, F., Inwards, D.J., Ketterer, N., Farooq, U., Fitoussi, O., Macon, W.R., Molina, T.J., Syrbu, S., Feldman, A.L., Slager, S.L., Weiner, G.J., Ansell, S.M., Cerhan, J.R., Salles, G.A., Witzig, T.E., Tilly, H. & Nowakowski, G.S. (2018) Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. Journal of Clinical Oncology, 36, 1603-1610.
Mead, G.M., Sydes, M.R., Walewski, J., Grigg, A., Hatton, C.S., Pescosta, N., Guarnaccia, C., Lewis, M.S., McKendrick, J., Stenning, S.P., Wright, D. & Norbert, P.; UKLG LY06 Collaborators. (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Annals of Oncology, 13, 1264-1274.
Mead, G.M., Barrans, S.L., Qian, W., Walewski, J., Radford, J.A., Wolf, M., Clawson, S.M., Stenning, S.P., Yule, C.L. & Jack, A.S.UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group. (2008) A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood, 112, 2248-2260.
Molyneux, E.M., Rochford, R., Griffin, B., Newton, R., Jackson, G., Menon, G., Harrison, C.J., Israels, T. & Bailey, S. (2012) Burkitt ’s lymphoma. Lancet, 379, 1234-1244.
Oeffinger, K.C., Mertens, A.C., Sklar, C.A., Kawashima, T., Hudson, M.M., Meadows, A.T., Friedman, D.L., Marina, N., Hobbie, W., Kadan-Lottick, N.S., Schwartz, C.L., Leisenring, W. & Robison, L.L. (2006) Chronic health conditions in adult survivors of childhood cancer. New England Journal of Medicine, 355, 1572-1582.
Oriol, A., Ribera, J., Bergua, J., Giménez Mesa, E., Grande, C., Esteve, J., Brunet, S., Moreno, M., Escoda, L., Hernandez-Rivas, J. & Hoelzer, D. (2008) High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma. Cancer, 113, 117-125.
Ribera, J.-M., García, O., Grande, C., Esteve, J., Oriol, A., Bergua, J., González-Campos, J., Vall-llovera, F., Tormo, M., Hernández-Rivas, J.-M., García, D., Brunet, S., Alonso, N., Barba, P., Miralles, P., Llorente, A., Montesinos, P., Moreno, M.-J., Hernández-Rivas, J.-Á. & Bernal, T. (2013) Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status. Cancer, 119, 1660-1668.
Ribrag, V., Koscielny, S., Bosq, J., Leguay, T., Casasnovas, O., Fornecker, L.M., Recher, C., Ghesquieres, H., Morschhauser, F., Girault, S., Gouill, S.Le, Ojeda-Uribe, M., Mariette, C., Cornillon, J., Cartron, G., Verge, V., Chassagne-Clément, C., Dombret, H., Coiffier, B., Lamy, T., Tilly, H. & Salles, G. (2016) Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. The Lancet, 387, 2402-2411.
Rizzieri, D.A., Johnson, J.L., Byrd, J.C., Lozanski, G., Blum, K.A., Powell, B.L., Shea, T.C., Nattam, S., Hoke, E., Cheson, B.D. & Larson, R.A. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10 002. British Journal of Haematology, 165, 102-111.
Rodrigo, J.A., Hicks, L.K., Cheung, M.C., Song, K.W., Ezzat, H., Leger, C.S., Boro, J., Montaner, J.S.G., Harris, M. & Leitch, H.A. (2012) HIV-associated Burkitt lymphoma: good efficacy and tolerance of intensive chemotherapy including CODOX-M/IVAC with or without rituximab in the HAART era. Advances in Hematology, 2012, 1-9.
Roschewski, M., Dunleavy, K., Abramson, J.S., Link, B.K., Parekh, S., Jagadeesh, D., Bierman, P., Mitsuyasu, R.T., Battini, R., Watson, P.R., Peace, D., Hanna, W., Powell, B.L., O’Brien, T.E., King, D., Melani, C., Lucas, A., Steinberg, S.M., Kahl, B.S., Friedberg, J.W., Little, R.F., Bartlett, N.L., Fanale, M.A., Noy, A., & Wilson, W.H. (2017) Risk-adapted therapy in adults with Burkitt lymphoma: results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R. Blood, 130(Suppl. 1), 188.
Shi, Q., Schmitz, N., Ou, F.-S., Dixon, J.G., Cunningham, D., Pfreundschuh, M., Seymour, J.F., Jaeger, U., Habermann, T.M., Haioun, C., Tilly, H., Ghesquieres, H., Merli, F., Ziepert, M., Herbrecht, R., Flament, J., Fu, T., Coiffier, B. & Flowers, C.R. (2018) Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL). Journal of Clinical Oncology, 36, 2593-2602.
Smeland, S., Blystad, A.K., Kvaløy, S.O., Ikonomou, I.M., Delabie, J., Kvalheim, G., Hammerstrøm, J., Lauritzsen, G.F. & Holte, H. (2004) Treatment of Burkitt’s/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Annals of Oncology, 15, 1072-1078.
Soussain, C., Patte, C., Ostronoff, M., Delmer, A., Rigal-Huguet, F., Cambier, N., Leprise, P.Y., Francois, S., Cony-Makhoul, P., Harousseau, Jl, Janvier, M., Chauvenet, L., Witz, F. & Pico, J. (1995) Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood, 85, 664-674.
Swerdlow, S., Campo, E., Harris, N., Jaffe, E., Pileri, S., Stein, H., Thiele, J. & Vardiman, J. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. World Health Organization, Geneva, Switzerland. ISBN-10: 9283224310.
Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G.A., Zelenetz, A.D. & Jaffe, E.S. (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127, 2375-2390.
Swerdlow, S., Campo, E., Harris, N., Jaffe, E., Pileri, S., Stein, H. & Thiele, J. (2017) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. World Health Organization, Geneva, Switzerland. ISBN-10: 928324494X.
Thomas, D.A., Cortes, J., O’Brien, S., Pierce, S., Faderl, S., Albitar, M., Hagemeister, F.B., Cabanillas, F.F., Murphy, S., Keating, M.J. & Kantarjian, H. (1999) Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. Journal of Clinical Oncology, 17, 2461-2461.
Thomas, D.A., Faderl, S., O’Brien, S., Bueso-Ramos, C., Cortes, J., Garcia-Manero, G., Giles, F.J., Verstovsek, S., Wierda, W.G., Pierce, S.A., Shan, J., Brandt, M., Hagemeister, F.B., Keating, M.J., Cabanillas, F. & Kantarjian, H. (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer, 106, 1569-1580.
University of California Berkeley, (USA) & Max Planck Institute for Demographic Research, (Germany) Human Mortality Database. Available at: www.mortality.org [Accessed May 15, 2018].
Wästerlid, T., Brown, P.N., Hagberg, O., Hagberg, H., Pedersen, L.M., D’Amore, F. & Jerkeman, M. (2013) Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Annals of Oncology, 24, 1879-1886.
Westreich, D. & Cole, S.R. (2010) Invited commentary: positivity in practice. American Journal of Epidemiology, 171, 674-677.
Zhu, K.Y., Song, K.W., Connors, J.M., Leitch, H., Barnett, M.J., Ramadan, K., Slack, G.W., Abou Mourad, Y., Forrest, D.L., Hogge, D.E., Nantel, S.H., Narayanan, S., Nevill, T.J., Power, M.M., Sanford, D.S., Sutherland, H.J., Tucker, T., Toze, C.L., Sehn, L.H., Broady, R., & Gerrie, A.S. (2018) Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. British Journal of Haematology, 181, 782-790.